Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer
After 15 years, deep brain stimulation still effective in people with Parkinson’s
2 June 2021How harm reduction advocates and the tobacco industry capitalized on pandemic to promote nicotine
2 June 2021Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer
A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness.
